South Delhi Pharma, New Delhi, India
DANYELZA (naxitamab-gqgk) injection
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call 9891296838 or Email firstname.lastname@example.org to discuss.
INDICATIONS AND USAGE
Danyelza (naxitamab-gqgk) is a medication used to treat children aged 1 year or older and adults with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
DOSAGE FORMS & STRENGTHS: 40 mg/10 mL (4 mg/mL) in a single-dose vial.
Manufactured By: Y-mAbs Therapeutics
Prescribing Information URL: Click Here
DANYELZA (naxitamab-gqgk) injection, a FDA approved prescription medicine can be accessed in India and other part of countries. South Delhi Pharma can facilitate the supply on request under Named Patient Program by fulfilling the legal requirement (if applicable) on behalf patient. Share your mobile number and email ID to get “naxitamab-gqgk injections” cost price in India.
Get In Touch
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDM is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
M:+91-9891296838 / P:+91-11- 26532129
Medical Uses of naxitamab-gqgk injection
Naxitamab is used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to treat people one year of age and older with high-risk neuroblastoma in bone or bone marrow whose tumor did not respond to or has come back after previous treatments and has shown a partial response, minor response, or stable disease to prior therapy.
Naxitamab, is an anti-cancer medication. It is a monoclonal antibody used in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) for people one year of age and older with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow demonstrating a partial response, minor response, or stable disease to prior therapy. The U.S. Food and Drug Administration (FDA) granted the application for naxitamab priority review, breakthrough therapy, and, orphan drug designations. The FDA issued a priority review voucher for this rare pediatric disease product application and was later granted a priority approval.
Get Access To DANYELZA (naxitamab-gqgk) injection In India
Brand Name "DANYELZA (naxitamab-gqgk) injection" or Generic Name "naxitamab-gqgk injection" can be imported for personal use under "Named Patient Program" treatment in Delhi, Mumbai, Kolkata, Chennai, Bangalore, Hyderabad, Ahmedabad, Pune, Surat, Jaipur, Coimbatore, Noida, Gurgaon, Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura and Sikkim, India. Contact us at email@example.com, firstname.lastname@example.org or call/WhatsApp at +91-9891296838 to get access as per norms.